Summary of the RISK MANAGEMENT PLAN (RMP) for VAFSEO (VADADUSTAT)

Version: 2.0

Marketing Authorisation Holder (MAH): Voisin Consulting CH Sàrl

Document Date: 03 August 2023

Based on EU RMP version 2.0, 21 Feb 2023 (Data Lock Point: 18 Aug 2021)

Disclaimer:

The Risk Management Plan (RMP) is a comprehensive document submitted as part of the application dossier for market approval of a medicine. The RMP summary contains information on the medicine's safety profile and explains the measures that are taken in order to further investigate and follow the risks as well as to prevent or minimise them.

The RMP summary of "VAFSEO" is a concise document and does not claim to be exhaustive.

As the RMP is an international document, the summary might differ from the "Arzneimittelinformation / Information sur le médicament" approved and published in Switzerland, e.g. by mentioning risks occurring in populations or indications not included in the Swiss authorization.

Please note that the reference document which is valid and relevant for the effective and safe use of "VAFSEO" in Switzerland is the "Arzneimittelinformation / Information sur le médicament" (see www.swissmedic.ch) approved and authorized by Swissmedic. Voisin Consulting CH Sàrl is fully responsible for the accuracy and correctness of the content of the published summary RMP of VAFSEO.

Summary of the Risk Management Plan for VAFSEO (vadadustat).

This is a summary of the risk management plan (RMP) for VAFSEO. The RMP details important risks of VAFSEO, how these risks can be minimised, and how more information will be obtained about VAFSEO's risks and uncertainties (missing information).

VAFSEO's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how vadadustat should be used.

This summary of the RMP for VAFSEO should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of VAFSEO's RMP.

I. The Medicine and What it is Used for

VAFSEO is authorised for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis (see SmPC for the full indication). It contains vadadustat as the active substance and it is given by oral route. Pharmaceutical forms and strengths are as follows.

VAFSEO (vadadustat) is approved as a film-coated, immediate-release tablet in 150 mg, 300 mg, and 450 mg dosage strengths.

Further information about the evaluation of VAFSEO's benefits can be found in VAFSEO's EPAR, including in its plain-language summary, available on the EMA website, under the medicine's webpage.

II. Risks Associated with the medicine and activities to minimise or further characterize the risks

Important risks of VAFSEO, together with measures to minimise such risks and the proposed studies for learning more about VAFSEO's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status - the way a medicine is supplied to the patient (e.g., with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of VAFSEO is not yet available, it is listed under `missing information' below.

II.A: List of Important Risks and Missing Information

Important risks of VAFSEO are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of VAFSEO. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g., on the long-term use of the medicine).

Table 1 II.A-1: List of Important Risks and Missing Information	
Important Identified Risks	None
Important Potential Risks	Hepatotoxicity
Missing Information	None

II.B: Summary of Important Risks

Table 2 II.B-1: Important Potential Risk: Hepatotoxicity	
Evidence for linking the risk to the medicine	The source of evidence was hepatic events data from clinical studies.
Risk factors and risk groups	There are currently no known risk factors or risk groups for drug-induced hepatotoxicity. In general, known risk factors for hepatotoxicity include age, gender, drug interactions, high alcohol intake, malnutrition, HCV, HBV, HIV infections, and genetic predisposition. Patients with hepatic steatosis, alcohol liver disease, and other acquired or inherited liver diseases may be at a higher risk for developing hepatotoxicity. Patients pre- or concomitantly treated with other medications associated with hepatotoxicity may be at higher risk for hepatotoxicity.
Risk minimisation measures	**Routine risk minimisation measures:** Inclusion in SmPC: - Section 4.2: Posology and method of administration - Section 4.4: Special warnings and precautions for use. - Section 4.8: Undesirable effects. PL section: - Section 2: What you need to know before you take VAFSEO (subsection: Warnings and precautions) - Section 4: Possible side effects **Additional risk minimisation measures:** None

II.C: Post-authorisation Development Plan

II.C.1 Studies Which are Conditions of the Marketing Authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of vadadustat.

II.C.2 Other Studies in Post-authorisation Development Plan

There are no studies required for vadadustat.